FLT3 and acute myeloid leukemia: In the pathogenesis of AML, mutation or aberrant activation of TKs (e.g. FLT3-ITD) promotes the acquisition of drug resistance and immune escape by LSCs through the remodeling of the metabolic network and the immune microenvironment, ultimately resulting in the formation of a distinctive “metabolic-immune double barrier” (81).